Cargando…

Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification

Background: The government of India is committed to eliminating tuberculosis (TB) by 2025 under the National Tuberculosis Elimination Programme which provides free investigations and treatment as well as incentives for nutritional support during their treatment course. Many TB patients prefer to see...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Ratnesh, Rana, Rishabh K, Kujur, Anit, Jahnavi, G, Kumar, Mithilesh, Venugopal, Vinayagamoorthy, Priya, Neha, Kujur, Manisha, Jha, Ravi Ranjan, Barnwal, Rajan, Nishant, Nikhil, Murmu, Nisha, Pathak, Rajeev, T, Anupama, Prasad, Ranjit, Dayal, Rakesh, Modi, Bhavesh, Purty, Anil J, BN, Sharath, Nair, Dina, Kumar, Dewesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656432/
https://www.ncbi.nlm.nih.gov/pubmed/38021489
http://dx.doi.org/10.7759/cureus.47296
_version_ 1785137004874301440
author Sinha, Ratnesh
Rana, Rishabh K
Kujur, Anit
Jahnavi, G
Kumar, Mithilesh
Venugopal, Vinayagamoorthy
Priya, Neha
Kujur, Manisha
Jha, Ravi Ranjan
Barnwal, Rajan
Nishant, Nikhil
Murmu, Nisha
Pathak, Rajeev
T, Anupama
Prasad, Ranjit
Dayal, Rakesh
Modi, Bhavesh
Purty, Anil J
BN, Sharath
Nair, Dina
Kumar, Dewesh
author_facet Sinha, Ratnesh
Rana, Rishabh K
Kujur, Anit
Jahnavi, G
Kumar, Mithilesh
Venugopal, Vinayagamoorthy
Priya, Neha
Kujur, Manisha
Jha, Ravi Ranjan
Barnwal, Rajan
Nishant, Nikhil
Murmu, Nisha
Pathak, Rajeev
T, Anupama
Prasad, Ranjit
Dayal, Rakesh
Modi, Bhavesh
Purty, Anil J
BN, Sharath
Nair, Dina
Kumar, Dewesh
author_sort Sinha, Ratnesh
collection PubMed
description Background: The government of India is committed to eliminating tuberculosis (TB) by 2025 under the National Tuberculosis Elimination Programme which provides free investigations and treatment as well as incentives for nutritional support during their treatment course. Many TB patients prefer to seek treatment from the private sector which sometimes leads to financial constraints for the patients. Our study aims to find the burden of TB patients in the private sector and the expenses borne by them for their treatment. Methodology: Sales data of rifampicin-containing formulation drug consumption in the private sector of six districts of Jharkhand was collected from Clearing and Forwarding agencies. Based on the drug sales data, the total incurring costs of the drugs, total number of patients, and cost per patient seeking treatment from the private sector were calculated for the year 2015-2021. ANOVA and the post hoc test (Tukey honestly significant difference (HSD)) were applied for analysis. Results: There was a marked difference amongst all the districts in relation to all the variables namely total costs, cost per patient, and total private patients seeking treatment from the private sector which was statistically significant (p < 0.001). East Singhbhum had the highest out-of-pocket expense and private patients as compared to all six districts. Lohardaga showed the sharpest decline in total private patients from 2015 to 2021. The average cost borne by private patients in 2015 was INR 1821 (95% CI 1086 - 2556) which decreased to INR 1033 (95% CI 507 - 1559) in 2021. Conclusion: From the study, it was concluded that the purchase of medicines for TB treatment from the private sector is one of the essential elements in out-of-pocket expenditure (OOPE) borne by TB patients. Hence, newer initiatives should be explored to foresee the future OOPE borne by the patients and decrease OOPE-induced poverty.
format Online
Article
Text
id pubmed-10656432
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106564322023-10-18 Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification Sinha, Ratnesh Rana, Rishabh K Kujur, Anit Jahnavi, G Kumar, Mithilesh Venugopal, Vinayagamoorthy Priya, Neha Kujur, Manisha Jha, Ravi Ranjan Barnwal, Rajan Nishant, Nikhil Murmu, Nisha Pathak, Rajeev T, Anupama Prasad, Ranjit Dayal, Rakesh Modi, Bhavesh Purty, Anil J BN, Sharath Nair, Dina Kumar, Dewesh Cureus Preventive Medicine Background: The government of India is committed to eliminating tuberculosis (TB) by 2025 under the National Tuberculosis Elimination Programme which provides free investigations and treatment as well as incentives for nutritional support during their treatment course. Many TB patients prefer to seek treatment from the private sector which sometimes leads to financial constraints for the patients. Our study aims to find the burden of TB patients in the private sector and the expenses borne by them for their treatment. Methodology: Sales data of rifampicin-containing formulation drug consumption in the private sector of six districts of Jharkhand was collected from Clearing and Forwarding agencies. Based on the drug sales data, the total incurring costs of the drugs, total number of patients, and cost per patient seeking treatment from the private sector were calculated for the year 2015-2021. ANOVA and the post hoc test (Tukey honestly significant difference (HSD)) were applied for analysis. Results: There was a marked difference amongst all the districts in relation to all the variables namely total costs, cost per patient, and total private patients seeking treatment from the private sector which was statistically significant (p < 0.001). East Singhbhum had the highest out-of-pocket expense and private patients as compared to all six districts. Lohardaga showed the sharpest decline in total private patients from 2015 to 2021. The average cost borne by private patients in 2015 was INR 1821 (95% CI 1086 - 2556) which decreased to INR 1033 (95% CI 507 - 1559) in 2021. Conclusion: From the study, it was concluded that the purchase of medicines for TB treatment from the private sector is one of the essential elements in out-of-pocket expenditure (OOPE) borne by TB patients. Hence, newer initiatives should be explored to foresee the future OOPE borne by the patients and decrease OOPE-induced poverty. Cureus 2023-10-18 /pmc/articles/PMC10656432/ /pubmed/38021489 http://dx.doi.org/10.7759/cureus.47296 Text en Copyright © 2023, Sinha et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Preventive Medicine
Sinha, Ratnesh
Rana, Rishabh K
Kujur, Anit
Jahnavi, G
Kumar, Mithilesh
Venugopal, Vinayagamoorthy
Priya, Neha
Kujur, Manisha
Jha, Ravi Ranjan
Barnwal, Rajan
Nishant, Nikhil
Murmu, Nisha
Pathak, Rajeev
T, Anupama
Prasad, Ranjit
Dayal, Rakesh
Modi, Bhavesh
Purty, Anil J
BN, Sharath
Nair, Dina
Kumar, Dewesh
Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification
title Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification
title_full Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification
title_fullStr Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification
title_full_unstemmed Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification
title_short Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification
title_sort trends of private drugs' sales and costs incurred by patients on anti-tuberculosis drugs in selected districts of jharkhand (2022): results from sub-national tb-free certification
topic Preventive Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656432/
https://www.ncbi.nlm.nih.gov/pubmed/38021489
http://dx.doi.org/10.7759/cureus.47296
work_keys_str_mv AT sinharatnesh trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT ranarishabhk trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT kujuranit trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT jahnavig trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT kumarmithilesh trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT venugopalvinayagamoorthy trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT priyaneha trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT kujurmanisha trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT jharaviranjan trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT barnwalrajan trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT nishantnikhil trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT murmunisha trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT pathakrajeev trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT tanupama trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT prasadranjit trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT dayalrakesh trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT modibhavesh trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT purtyanilj trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT bnsharath trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT nairdina trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification
AT kumardewesh trendsofprivatedrugssalesandcostsincurredbypatientsonantituberculosisdrugsinselecteddistrictsofjharkhand2022resultsfromsubnationaltbfreecertification